drugset / Trial / NCT02612506
Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.
Timeline
- Start
- 2015-10
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hepalatide | Protein / enzyme biologic | 0.21 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 0.525 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 2.1 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 4.2 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 6.3 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 8.4 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 10.5 mg | Subcutaneous |